CA2332652C - Steroides heterocycliques c17 insatures .delta.16 utilises comme inhibiteurs de lyase c17-20 steroides - Google Patents

Steroides heterocycliques c17 insatures .delta.16 utilises comme inhibiteurs de lyase c17-20 steroides Download PDF

Info

Publication number: CA2332652C
Authority: CA; Canada
Prior art keywords: compound; dien; androsta; steroid; formula
Prior art date: 1993-10-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA002332652A

Other languages

English (en)

Other versions

CA2332652A1 (fr

Inventor

Norton P. Peet

Joseph P. Burkhart

Cynthia P. Gates

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Aventis Pharmaceuticals Inc

Original Assignee

Merrell Dow Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-10-27

Filing date

1994-09-29

Publication date

2003-06-03

1994-09-29 Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc

1994-09-29 Priority claimed from CA002173729A external-priority patent/CA2173729C/fr

1995-05-04 Publication of CA2332652A1 publication Critical patent/CA2332652A1/fr

2003-06-03 Application granted granted Critical

2003-06-03 Publication of CA2332652C publication Critical patent/CA2332652C/fr

2014-09-29 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

150000003431 steroids Chemical class 0.000 title claims abstract description 53
-1 heterocyclic steroids Chemical class 0.000 title abstract description 41
239000002697 lyase inhibitor Substances 0.000 title abstract description 7
150000001875 compounds Chemical class 0.000 claims description 97
238000000034 method Methods 0.000 claims description 30
238000002360 preparation method Methods 0.000 claims description 27
102000004317 Lyases Human genes 0.000 claims description 20
108090000856 Lyases Proteins 0.000 claims description 20
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
230000002401 inhibitory effect Effects 0.000 claims description 16
230000000694 effects Effects 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 12
239000000546 pharmaceutical excipient Substances 0.000 claims description 8
239000008194 pharmaceutical composition Substances 0.000 claims description 6
125000006239 protecting group Chemical group 0.000 claims description 6
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
239000001257 hydrogen Substances 0.000 claims description 5
229910052739 hydrogen Inorganic materials 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
229910052760 oxygen Inorganic materials 0.000 claims description 4
229910052717 sulfur Inorganic materials 0.000 claims description 3
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
229910000041 hydrogen chloride Inorganic materials 0.000 claims 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims 1
230000001590 oxidative effect Effects 0.000 claims 1
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 96
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 84
238000006243 chemical reaction Methods 0.000 description 55
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 53
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 48
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 31
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 29
239000007787 solid Substances 0.000 description 27
239000000243 solution Substances 0.000 description 25
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
239000000741 silica gel Substances 0.000 description 22
229910002027 silica gel Inorganic materials 0.000 description 22
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 21
239000000460 chlorine Substances 0.000 description 21
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 19
238000003756 stirring Methods 0.000 description 19
238000003818 flash chromatography Methods 0.000 description 17
239000012267 brine Substances 0.000 description 16
239000012141 concentrate Substances 0.000 description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
208000035475 disorder Diseases 0.000 description 16
238000010992 reflux Methods 0.000 description 16
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 16
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 15
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
235000008504 concentrate Nutrition 0.000 description 15
239000012298 atmosphere Substances 0.000 description 14
230000001419 dependent effect Effects 0.000 description 14
229910000042 hydrogen bromide Inorganic materials 0.000 description 14
229910052757 nitrogen Inorganic materials 0.000 description 14
239000003960 organic solvent Substances 0.000 description 14
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 14
239000002904 solvent Substances 0.000 description 13
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
239000003098 androgen Substances 0.000 description 12
239000000047 product Substances 0.000 description 12
238000003556 assay Methods 0.000 description 11
230000005764 inhibitory process Effects 0.000 description 11
239000000203 mixture Substances 0.000 description 11
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 10
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 8
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
238000005160 1H NMR spectroscopy Methods 0.000 description 7
235000013877 carbamide Nutrition 0.000 description 7
239000000262 estrogen Substances 0.000 description 7
238000001953 recrystallisation Methods 0.000 description 7
239000004202 carbamide Substances 0.000 description 6
229940011871 estrogen Drugs 0.000 description 6
239000012044 organic layer Substances 0.000 description 6
235000017557 sodium bicarbonate Nutrition 0.000 description 6
229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 5
241000282567 Macaca fascicularis Species 0.000 description 5
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 5
125000000623 heterocyclic group Chemical group 0.000 description 5
229920006395 saturated elastomer Polymers 0.000 description 5
239000000725 suspension Substances 0.000 description 5
230000002381 testicular Effects 0.000 description 5
238000012360 testing method Methods 0.000 description 5
101150041968 CDC13 gene Proteins 0.000 description 4
FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 4
230000005526 G1 to G0 transition Effects 0.000 description 4
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000000969 carrier Substances 0.000 description 4
QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 4
FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 4
239000003480 eluent Substances 0.000 description 4
239000010410 layer Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
229960002847 prasterone Drugs 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
238000007363 ring formation reaction Methods 0.000 description 4
239000007858 starting material Substances 0.000 description 4
239000000758 substrate Substances 0.000 description 4
229960003604 testosterone Drugs 0.000 description 4
MSXCJZGCNBCMNA-PTRTWWQBSA-N (8r,9s,10r,13s,14s)-10,13-dimethyl-17-thiophen-2-yl-1,2,4,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CS1 MSXCJZGCNBCMNA-PTRTWWQBSA-N 0.000 description 3
SHGMACJGBKYTPH-HSDNQCAASA-N (8r,9s,10r,13s,14s)-17-(2-amino-1,3-thiazol-4-yl)-10,13-dimethyl-1,2,4,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CSC(N)=N1 SHGMACJGBKYTPH-HSDNQCAASA-N 0.000 description 3
JERGUCIJOXJXHF-TVWVXWENSA-N 17alpha-hydroxypregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JERGUCIJOXJXHF-TVWVXWENSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
229940030486 androgens Drugs 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
238000001816 cooling Methods 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
239000006260 foam Substances 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
230000003228 microsomal effect Effects 0.000 description 3
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
238000011474 orchiectomy Methods 0.000 description 3
ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 description 3
229960000249 pregnenolone Drugs 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
239000012453 solvate Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
230000036962 time dependent Effects 0.000 description 3
XJPMNFQJAVVEEY-BQBMVXNTSA-N (8r,9s,10r,13s,14s)-10,13-dimethyl-17-[2-(methylamino)-1,3-thiazol-4-yl]-1,2,4,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-3-one Chemical compound S1C(NC)=NC(C=2[C@]3(CC[C@@H]4[C@@]5(C)CCC(=O)CC5=CC[C@H]4[C@@H]3CC=2)C)=C1 XJPMNFQJAVVEEY-BQBMVXNTSA-N 0.000 description 2
BQMZLBAGMWSMAE-HSDNQCAASA-N (8r,9s,10r,13s,14s)-17-(2-amino-1,3-oxazol-4-yl)-10,13-dimethyl-1,2,4,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)CC3=CC2)C)CC[C@@]11C)C=C1C1=COC(N)=N1 BQMZLBAGMWSMAE-HSDNQCAASA-N 0.000 description 2
NAEGTSZLOLATRV-HSDNQCAASA-N (8r,9s,10r,13s,14s)-17-(2-amino-1h-imidazol-5-yl)-10,13-dimethyl-1,2,4,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CNC(N)=N1 NAEGTSZLOLATRV-HSDNQCAASA-N 0.000 description 2
KIKOVPWAAHVZLL-PTRTWWQBSA-N (8r,9s,10r,13s,14s)-17-(furan-2-yl)-10,13-dimethyl-1,2,4,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CO1 KIKOVPWAAHVZLL-PTRTWWQBSA-N 0.000 description 2
URAROPWCRVTQCV-VPSDZCSPSA-N (8r,9s,10r,13s,14s)-17-(furan-3-yl)-10,13-dimethyl-1,2,4,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)CC3=CC2)C)CC[C@@]11C)C=C1C=1C=COC=1 URAROPWCRVTQCV-VPSDZCSPSA-N 0.000 description 2
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
YLFRRPUBVUAHSR-RRPFGEQOSA-N 16,17-didehydropregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC=C(C(=O)C)[C@@]1(C)CC2 YLFRRPUBVUAHSR-RRPFGEQOSA-N 0.000 description 2
YLFRRPUBVUAHSR-UHFFFAOYSA-N 16-dehydro-pregnenolone Natural products C1C=C2CC(O)CCC2(C)C2C1C1CC=C(C(=O)C)C1(C)CC2 YLFRRPUBVUAHSR-UHFFFAOYSA-N 0.000 description 2
LXWLEQZDXOQZGW-UHFFFAOYSA-N 3-bromofuran Chemical compound BrC=1C=COC=1 LXWLEQZDXOQZGW-UHFFFAOYSA-N 0.000 description 2
XCMISAPCWHTVNG-UHFFFAOYSA-N 3-bromothiophene Chemical compound BrC=1C=CSC=1 XCMISAPCWHTVNG-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
201000004384 Alopecia Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
229910021590 Copper(II) bromide Inorganic materials 0.000 description 2
102000018832 Cytochromes Human genes 0.000 description 2
108010052832 Cytochromes Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
206010020112 Hirsutism Diseases 0.000 description 2
229940122014 Lyase inhibitor Drugs 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
KQJQICVXLJTWQD-UHFFFAOYSA-N N-Methylthiourea Chemical compound CNC(N)=S KQJQICVXLJTWQD-UHFFFAOYSA-N 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
206010047486 Virilism Diseases 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
206010068168 androgenetic alopecia Diseases 0.000 description 2
AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 2
AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 2
229960005471 androstenedione Drugs 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 2
229960000452 diethylstilbestrol Drugs 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
239000006187 pill Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000002243 precursor Substances 0.000 description 2
230000001172 regenerating effect Effects 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000006188 syrup Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
125000000335 thiazolyl group Chemical group 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
229930192474 thiophene Natural products 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
JKOYLMZNJPFQNV-RFOVXIPZSA-N (3s,8r,9s,10r,13s,14s)-10,13-dimethyl-17-thiophen-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C=1C=CSC=1 JKOYLMZNJPFQNV-RFOVXIPZSA-N 0.000 description 1
FSIKLVCOAJYNII-YGQHUFLISA-N (3s,8r,9s,10r,13s,14s)-17-(2-amino-1,3-oxazol-4-yl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=COC(N)=N1 FSIKLVCOAJYNII-YGQHUFLISA-N 0.000 description 1
GHSXTHNGPDVPPO-YGQHUFLISA-N (3s,8r,9s,10r,13s,14s)-17-(2-amino-1,3-thiazol-4-yl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CSC(N)=N1 GHSXTHNGPDVPPO-YGQHUFLISA-N 0.000 description 1
BGIQEPPPFFSKLP-FYVXYBBASA-N (3s,8r,9s,10r,13s,14s)-3-[tert-butyl(dimethyl)silyl]oxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](O[Si](C)(C)C(C)(C)C)C1 BGIQEPPPFFSKLP-FYVXYBBASA-N 0.000 description 1
JTAWEPAXRAUKMM-VPSDZCSPSA-N (8r,9s,10r,13s,14s)-10,13-dimethyl-17-thiophen-3-yl-1,2,4,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)CC3=CC2)C)CC[C@@]11C)C=C1C=1C=CSC=1 JTAWEPAXRAUKMM-VPSDZCSPSA-N 0.000 description 1
NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
KEWLVUBYGUZFKX-UHFFFAOYSA-N 2-ethylguanidine Chemical compound CCNC(N)=N KEWLVUBYGUZFKX-UHFFFAOYSA-N 0.000 description 1
AMATXUCYHHHHHB-UHFFFAOYSA-N 5,5-dibromo-1,3-diazinane-2,4,6-trione Chemical compound BrC1(Br)C(=O)NC(=O)NC1=O AMATXUCYHHHHHB-UHFFFAOYSA-N 0.000 description 1
102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
101100381997 Danio rerio tbc1d32 gene Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
244000246386 Mentha pulegium Species 0.000 description 1
235000016257 Mentha pulegium Nutrition 0.000 description 1
235000004357 Mentha x piperita Nutrition 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
101100381999 Mus musculus Tbc1d32 gene Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
MUCRYNWJQNHDJH-OADIDDRXSA-N Ursonic acid Chemical class C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C MUCRYNWJQNHDJH-OADIDDRXSA-N 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
239000003708 ampul Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
238000010936 aqueous wash Methods 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
RJNJWHFSKNJCTB-UHFFFAOYSA-N benzylurea Chemical compound NC(=O)NCC1=CC=CC=C1 RJNJWHFSKNJCTB-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000005893 bromination reaction Methods 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
235000015218 chewing gum Nutrition 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
238000004040 coloring Methods 0.000 description 1
229940124301 concurrent medication Drugs 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
SDIXRDNYIMOKSG-UHFFFAOYSA-L disodium methyl arsenate Chemical compound [Na+].[Na+].C[As]([O-])([O-])=O SDIXRDNYIMOKSG-UHFFFAOYSA-L 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
229960001484 edetic acid Drugs 0.000 description 1
230000008030 elimination Effects 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
229960003399 estrone Drugs 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
230000036541 health Effects 0.000 description 1
235000001050 hortel pimenta Nutrition 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
238000009533 lab test Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
229940012189 methyl orange Drugs 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960001047 methyl salicylate Drugs 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
210000001589 microsome Anatomy 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
238000007248 oxidative elimination reaction Methods 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000008057 potassium phosphate buffer Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
239000012264 purified product Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000006965 reversible inhibition Effects 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
239000012056 semi-solid material Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
229910052814 silicon oxide Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
150000003585 thioureas Chemical class 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
150000003672 ureas Chemical class 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CA002332652A 1993-10-27 1994-09-29 Steroides heterocycliques c17 insatures .delta.16 utilises comme inhibiteurs de lyase c17-20 steroides Expired - Fee Related CA2332652C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US14367993A	1993-10-27	1993-10-27
US08/143,679		1993-10-27
CA002173729A CA2173729C (fr)	1993-10-27	1994-09-29	Steroides heterocycliques c17 insatures .delta.16 utilises comme inhibiteurs de lyase c17-20 steroides

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002173729A Division CA2173729C (fr)	1993-10-27	1994-09-29	Steroides heterocycliques c17 insatures .delta.16 utilises comme inhibiteurs de lyase c17-20 steroides

Publications (2)

Publication Number	Publication Date
CA2332652A1 CA2332652A1 (fr)	1995-05-04
CA2332652C true CA2332652C (fr)	2003-06-03

Family

ID=25678415

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002332652A Expired - Fee Related CA2332652C (fr)	1993-10-27	1994-09-29	Steroides heterocycliques c17 insatures .delta.16 utilises comme inhibiteurs de lyase c17-20 steroides

Country Status (1)

Country	Link
CA (1)	CA2332652C (fr)

1994
- 1994-09-29 CA CA002332652A patent/CA2332652C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2332652A1 (fr)	1995-05-04

Legal Events

Date	Code	Title	Description
2001-02-16	EEER	Examination request
2005-09-29	MKLA	Lapsed
2023-05-26	MKLA	Lapsed	Effective date: 20050929

Publication	Publication Date	Title
CA2173729C (fr)	2001-05-15	Steroides heterocycliques c17 insatures .delta.16 utilises comme inhibiteurs de lyase c17-20 steroides
CA1319362C (fr)	1993-06-22	Derives androstenedione substitues en 4, et procede pour leur preparation
DK163520B (da)	1992-03-09	Substitueret androsta-1,4-dien-3,17-dioner, fremgangsmaade til fremstilling deraf, praeparater indeholdende saadanne forbindelser samt anvendelsen af disse til fremstilling af farmaceutiske praeparater
CS9100274A2 (en)	1991-12-17	17-beta-substituted 4-aza-5 alpha-androstane-3-one derivative and method of its preparation
CA2768453A1 (fr)	2011-01-27	Derives 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-diene-11-acyloxyalcenylphenyle, procedes de preparation et utilisation pour le traitement de maladies
JPH08245687A (ja)	1996-09-24	テストステロン５α−還元酵素阻害剤としての３−カルボキシ−アンドロスト−３，５−ジエンのＮ−モノ置換アダマンチル／ノルボルナニル１７β−カルバミド
AU2018279205B2 (en)	2021-04-15	15.beta.-(3-propanamido)-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases
IE65269B1 (en)	1995-10-18	Aromatase inhibitors
JPH08510733A (ja)	1996-11-12	４−アミノ−１７β−（シクロプロピロキシ）アンドロスト−４−エン−３−オン、４−アミノ−１７β−（シクロプロピルアミノ）アンドロスト−４−エン−３−オン及びＣ▲下１７−２０▼リアーゼ及び５α−レダクターゼ阻害剤としての関連する化合物類
KR970007948B1 (ko)	1997-05-19	17-치환된 안드로스타-1,4-디엔-3-온 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
JPH04117394A (ja)	1992-04-17	１０位置に置換エチル基を含有する新規のステロイド化合物、それらの製造方法、それらの薬剤としての使用及びそれらを含有する製薬組成物
CA1310957C (fr)	1992-12-01	Derives 10-alkynylestrene et procede pour leur preparation
CA2332652C (fr)	2003-06-03	Steroides heterocycliques c17 insatures .delta.16 utilises comme inhibiteurs de lyase c17-20 steroides
US5750744A (en)	1998-05-12	Process for the preparation of 4-amino- 4-3-ketosteroids via 4-nitro- 4-3-ketosteroids
CS231199B2 (en)	1984-10-15	Processing method of derivative of 6alpha-methylhydrokortisone
US20020019548A1 (en)	2002-02-14	20-Fluoro-17(20)-vinyl steroids
JP3338905B2 (ja)	2002-10-28	６位置換ステロイド誘導体
IE42124B1 (en)	1980-06-04	17,21-diesters of 17,21-dihydroxy steroids of the pregnaneseries
IL124213A (en)	2004-12-15	Sulfation of estrogen mixtures
JPS63222196A (ja)	1988-09-16	１−メチル−１５α−（１−オキシアルキル）−アンドロスタ−１，４−ジエン−３，１７−ジオン、その製法及びこの化合物を含むエストロゲン生合成抑制剤